secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001104659-23-098505
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment
-------------------------------------------------------------------------

- Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.
- Amendment to Japan license removes certain royalties and a $10M milestone but retains up to $45M in milestone payments.
- Exclusive license covers 13 Asian markets including South Korea, Taiwan, Hong Kong, and Southeast Asian nations.
- Maruho assumes Journey’s payment obligations to Dermira (Eli Lilly) for Territory sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/0001104659-23-098505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/tm2325553d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-098505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer